Unknown

Dataset Information

0

Management of Low and Intermediate Risk Adult Rhabdomyosarcoma: A Pooled Survival Analysis of 553 Patients.


ABSTRACT: This is the second-largest retrospective analysis addressing the controversy of whether adult rhabdomyosarcoma (RMS) should be treated with chemotherapy regimens adopted from pediatric RMS protocols or adult soft-tissue sarcoma protocols. A comprehensive database search identified 553 adults with primary non-metastatic RMS. Increasing age, intermediate-risk disease, no chemotherapy use, anthacycline-based and poor chemotherapy response were significant predictors of poor overall and progression-free survival. In contrast, combined cyclophosphamide-based, cyclophosphamide?+?anthracycline-based, or cyclophosphamide?+?ifosfamide?+?anthracycline-based regimens significantly improved outcomes. Intermediate-risk disease was a significant predictor of poor chemotherapy response. Overall survival of clinical group-III patients was significantly improved if they underwent delayed complete resection. Non-parameningeal clinical group-I patients had the best local control, which was not affected by additional adjuvant radiotherapy. This study highlights the superiority of chemotherapy regimens -adapted from pediatric protocols- compared to anthracycline-based regimens. There is lack of data to support the routine use of adjuvant radiotherapy for non-parameningeal group-I patients. Nonetheless, intensive local therapy should be always considered for those at high risk for local recurrence, including intermediate-risk disease, advanced IRS stage, large tumors or narrow surgical margins. Although practically difficult (due to tumor's rarity), there is a pressing need for high quality randomized controlled trials to provide further guidance.

SUBMITTER: Elsebaie MAT 

PROVIDER: S-EPMC6008292 | biostudies-literature | 2018 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

Management of Low and Intermediate Risk Adult Rhabdomyosarcoma: A Pooled Survival Analysis of 553 Patients.

Elsebaie Maha A T MAT   Amgad Mohamed M   Elkashash Ahmed A   Elgebaly Ahmed Saber AS   Ashal Gehad Gamal E L GGEL   Shash Emad E   Elsayed Zeinab Z  

Scientific reports 20180619 1


This is the second-largest retrospective analysis addressing the controversy of whether adult rhabdomyosarcoma (RMS) should be treated with chemotherapy regimens adopted from pediatric RMS protocols or adult soft-tissue sarcoma protocols. A comprehensive database search identified 553 adults with primary non-metastatic RMS. Increasing age, intermediate-risk disease, no chemotherapy use, anthacycline-based and poor chemotherapy response were significant predictors of poor overall and progression-  ...[more]

Similar Datasets

| PRJNA823798 | ENA
| PRJNA823799 | ENA
| S-EPMC6052659 | biostudies-literature
2021-07-27 | GSE178671 | GEO
| S-EPMC10548874 | biostudies-literature
| S-EPMC6717036 | biostudies-literature
| S-EPMC3207912 | biostudies-literature
| S-EPMC8719493 | biostudies-literature
2013-06-23 | E-GEOD-47109 | biostudies-arrayexpress
2023-11-30 | PXD041005 | Pride